Skip to main content

Table 2 Factors impacting adherence

From: Subjective patient-reported versus objective adherence to subcutaneous interferon β-1a in multiple sclerosis using RebiSmart®: the CORE study

Factor Objective adherence group Ordinal regression
Low
n = 15
Medium
n = 18
High
n = 20
OR 95% CI p
Patient age, years 41.0 (31.5–48.0) 48.5 (36.5–54.8) 53.5 (42.0–63.0) 1.064 1.016–1.114 0.008
Last known EDSS scorea 1.5 (1.0–2.0) 2.0 (1.5–3.3) 3.0 (2.0–3.8) 1.937 1.197–1.937 0.008
Neurologists’ estimations of adherence 10.0 (8.0–10.0) 9.0 (9.0–10.0) 10.0 (9.0–10.0) 1.528 1.019–2.291 0.04
Previous MS therapy 20.0% 33.0% 0.0% 0.344 0.089–1.340 0.124
Patient’s perceived relevance of ease of administration with RebiSmart® 9.0 (7.5–9.5) 10.0 (9.3–10.0) 10.0 (10.0–10.0) 1.578 1.080–2.307 0.018
Patient’s perceived relevance of storage of RebiSmart® 8.0 (5.5–8.0) 8.0 (5.3–10.0) 10.0 (8.0–10.0) 1.528 1.019–2.291 0.04
Being well informed about features of RebiSmart® 10.0 (9.0–10.0) 10.0 (10.0–10.0) 10.0 (10.0–10.0) 3.638 1.201–11.018 0.022
Patient’s perceived relevance of treatment in delaying progression of disease 10.0 (10.0–10.0) 10.0 (10.0–10.0) 10.0 (10.0–10.0) 1.063 0.644–1.753 0.812
Importance of frequency of administration 8.0 (7.0–9.0) 8.5 (6.3–10.0) 10.0 (5.0–10.0) 1.008 0.808–1.259 0.941
  1. Data were analyzed by ordinal regression and are reported as median (interquartile range, Q1–Q3), with the exception of ‘Previous MS therapy’ which is reported as percentage of ‘yes’ responses. P-values that were considered significant (p < 0.05) are in bold type
  2. Low adherence group: < 90%; medium adherence group: 90%–99.9%; high adherence group: > 99.9%
  3. CI confidence interval, EDSS expanded disability status scale, IFN interferon, OR odds ratio, sc subcutaneous, SD standard deviation
  4. aData missing for 2 patients